anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A new drug---"shining pearl" stomach safe capsule is involved in the invention. The prescription includes 8 Chinese traditional medicines. The preparing method is as following (1) calcite, sandalwood and faeces of flying squirrel are ground into fine powder; myrobalan fruit, amomum fruit are crushed into coarse powder; red sage root, nutgrass, galanga are cut in pieces. (2) red sage root, nutgrass, faces of flying squirrel are extracted three times by 70% alcohol, then these extractes are merged, concentrated into paste fire dried and crushed into powder. (3) Calcite, myrobalan, sandalwood and amomum fruit are decocted 3 times with water, then these extracted liquids are merged, concentrated into paste fire dried and crushed. By mixing above said powders and auxiliary materials evenly then packing the mixture into capsule. New drug provides effects of strengthening the spleen and stomach, activating vital energy to stop pain, promoting repair and regeneration of the coat epithelium of the stomach, promoting healing of ulcer. It applies to various sorts of chronic gastritis (superficial, atrophic, hypertrophic), gastric and duodenal ulcer, stomach pain and fullness and distention of the chest and abdomen, gastric cavity pain, retching and hiccup, diarrhea, deficiency-cold of the spleen and stomach.
BACKGROUND: Observational studies have suggested an association between birth weight and type 2 diabetes mellitus, but the causality between them has not been established. We aimed to obtain the causal relationship between birth weight with T2DM and quantify the mediating effects of potential modifiable risk factors.
METHODS: Two-step, two-sample Mendelian randomization (MR) techniques were applied using SNPs as genetic instruments for exposure and mediators. Summary data from genome-wide association studies (GWAS) for birth weight, T2DM, and a series of fatty acids traits and their ratios were leveraged. The inverse variance weighted (IVW) method was the main analysis approach. In addition, the heterogeneity test, horizontal pleiotropy test, Mendelian randomization pleiotropy residual sum and outlier (MR-PRESSO) test, and leave-one-out analysis were carried out to assess the robustness.
RESULTS: The IVW method showed that lower birth weight raised the risk of T2DM (β: -1.113, 95% CI: -1.573 ∼ -0.652). Two-step MR identified 4 of 17 candidate mediators partially mediating the effect of lower birth weight on T2DM, including ratio of polyunsaturated fatty acids to monounsaturated fatty acids (proportion mediated: 7.9%), ratio of polyunsaturated fatty acids to total fatty acids (7.2%), ratio of omega-6 fatty acids to total fatty acids (8.1%) and ratio of linoleic acid to total fatty acids ratio (6.0%).
CONCLUSIONS: Our findings supported a potentially causal effect of birth weight against T2DM with considerable mediation by modifiable risk factors. Interventions that target these factors have the potential to reduce the burden of T2DM attributable to low birth weight.
The present invention relates to a medicine liquid and a technology for removing freckles, chloasma and senile plaque at one time. The medicine liquid comprises the following traditional Chinese medicine raw materials, in weight percentages, 10% to 15% of licorice root, 10% to 15% of garden burnet root, 8% to 12% of common monkshood mother root, 8% to 12% of kusnezoff monkshood root and 4% to 6% of menthol. The components are added to 40% to 60 % of medical alcohol in weight percentage and are soaked for 1 to 10 days, and then, medicine dregs are removed so as to obtain traditional Chinese medicine liquid A; next, the Chinese medicine liquid A and western medicine components comprising, in weight percentages, 5% to 70% of Chinese medicine liquid A, 0.1% to 0.5% of dexamethasone, 0.5% to 1.5% of hydroquinone, 0.2% to 0.8% of dyclonine, 0.1% to 0.3% of dicaine and 30% to 90% of phenol are uniformly mixed with each other, and the medicine liquid for removing speckles is obtained. The technology for removing speckles comprises the following steps that firstly, the face is cleaned, and then, positions with speckles are dripped or smeared with the medicine liquid for removing speckles once or twice. The medicine liquid has the advantages of favorable effect for removing speckles and no side effect. After positions with speckles are dripped for seven times, the positions with speckles are removed and crusted, and new bright red skin grows.
The present invention relates, first, to the discovery, identification, and characterization of novel nucleic acid molecules, that are associated with PBC, Sjögren's syndrome, scleroderma, SLE, autoimmune thyroiditis and various other connective tissue disorders. The novel nucleotide sequences of the present invention are retroviral in origin and are indicative of a PBC retrovirus which bears a strong correlation with PBC. The present invention is based, in part, on the Applicant's data which is the first evidence to suggest that PBC patient's tissue may harbor a transmissible agent. The association of a retroviral infectious agent with PBC was first demonstrated by Applicants <i>in vitro</i> by co-culture of periportal lymph nodes derived from patients at time of transplantation and healthy biliary epithelium cells. The Applicant's discoveries as described herein, report the characterization of PBC-associated infectious agent as retroviral as demonstrated by electron microscopy and immunoblot reactivity. In addition, Applicants have characterized novel nucleotide sequences which are associated with the PBC-associated retrovirus.
Cosmetic and pharmaceutical compsn. for topical or oral admin. comprises a protecting agent with anti-radical and UV filtering properties comprising in a carrier: (i) at least one monomer and/or oligomer of a catechin-type phenol of plant origin; and (ii) at least one hydroxycinnamic acid of plant origin.  The extract is prepd. by extracting with warm water, precipitating tannins from the aq. phase by addn. of an inorganic salt pref. sodium chloride and filtering, treating the filtrate with EtOAc, concentrating the organic phase under reduced pressure, adding distilled water, eliminating EtOAc by evapn. under reduced pressure and at not more than 50  deg C, washing the aq. phase with chlorinated polar solvent, eliminating the solvent pref. under reduced pressure evaporation at not more than 50  deg C and drying.
Indomethacin is supplied in capsule dosage form for oral administration which contains either 25 mg or 50 mg of indomethacin and the following inactive ingredients: corn starch, D and C Yellow No. 10, FD and C Green No. 3, hydroxypropyl methylcellulose, lactose monohydrate, magnesium stearate, and polysorbate 80.

Indomethacin is a non-steroidal anti-inflammatory indole derivative designated chemically as 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid. Indomethacin is practically insoluble in water and sparingly soluble in alcohol. It has a pKa of 4.5 and is stable in neutral or slightly acidic media and decomposes in strong alkali.

The structural formula is:
More than 70 percent of ovarian cancer patients were diagnosed in the advanced stage. Currently the 5-year disease free survival (DFS) of stageⅢ-Ⅳovarian cancer patients was about 10 percent after first line chemotherapy. Dr Cai shumo developed adjuvant chemotherapy of "three steps" (ACTS) for advanced ovarian cancer after cytoreductive surgery, based on his 60+ years experience on gynecologic oncology. After the first step 6-8 cycle paclitaxel plus carboplatin chemotherapy, the chemo-sensative cancer cells were killed, but resistant/dormancy cell remained. The second step chemotherapy which is 6 cycle CTX+VP-16 every 4weeks, using different mechanism to kill cancer cells, may decrease the rate of recurrence within 6 month after first step chemotherapy, prolong platinum-free duration and also with acceptable side effects. After second step chemotherapy, in absence of 6 months platinum treatment, the previous G0 dormancy cell may become flexible to platinum treatment. Therefore, in the third step chemotherapy, CTX+CBP is used in every 8 week for 6 cycles. Comparing to using targeted therapy for maintaining therapy, the ACTS cost less.

In the previous observation study(CHINA ONCOLOGY 2013 Vol.23 No.12 p980), In study arm A, the patients received three-step chemotherapy after primary debulking surgery, step one with paclitaxel plus carboplatin (TC regimen), every 3 weeks for 6 to 8 cycles; step two with etoposide plus cyclophosphamide, every 4 weeks for 6 cycles; step three with carboplatin plus cyclophosphamide every eight weeks for six cycles. In control arm B, investigators retrospectively analysed 51 cases withⅢC-Ⅳstage ovarian cancer, who had completely response after standard chemotherapy with six to eight cycles of TC after primary surgery during 2007. Investigators compared the 5-year DFS between the two arms. Results: The 5-year DFS of 15 cases in arm A was 80%(12/15), which was signiifcantly higher than that of arm B (5.9%, 3/51, P\<0.01). Therefore we start this randomized open control clinic trial to evaluated the effect of ACTS on overall survival and its safety.

In2015, we launched ACTS study (NCT02562365), and the primary results showed benefit of ACTS on PFS and acceptable AE. Currently, PARP inhibit was shown to be effective in maintainance therapy in ovarian cancer especially approve for BRCA1/2 mutated pateints. However there is no standard maintainance therapy for BRCA1/2 wide-type ovarian cancer. Here we started ACTS-2 study to verify the effectivity and safety of ACTS in BRCA1/2 wide-type ovarian cancer patients.
<P>PROBLEM TO BE SOLVED: To provide therapeutic approach capable of delivering a diffusible biological product in a safe and effective form.  <P>SOLUTION: The subject implantable beads comprising agarose and optionally collagen and coated with agarose contain a cell sample producing a diffusible biological product. The beads may be used as an implant to modulate a recipient's immune response. The beads may also be used in vitro to promote the growth of a specific type cell, to produce a desirable product in the culture, or to suppress the growth of a specific cell. The implant may also suppress the growth of the specific cell after administration to a subject.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
PURPOSE:The titled composition useful as a drug obtained by blending IL-2 with a reductive substance. CONSTITUTION:An aqueous solution containing 1-80,000 units/ml IL-2 (preferably human IL-2) is blended with >=0.01mg/ml, preferably 0.05-20mg/ml reductive substance (e.g., reductive glutathione, thioctic acid, N-acetylcysteine, N- acetylhomocysteine, thiodiglycol, thioethanolamine, ascorbic acid, etc.) (as total amount when or more reductive substances are used) to give an interleukin-2 composition. Addition of human serum albumin, glucose, mannitol, glycine, etc. to it improves further stability, appearance when it is lyophilized, or state of solution or prevention of attachment of it to a container when it is dissolved. Injection preparation, or pharmaceutical preparation for administration to the oral cavity, eye, ear, or nose is used as a dosage form.
The invention provides Rhododendron nivale Hook. f. volatile oil which is prepared through the following steps: adding 15-20-fold water to dry Rhododendron nivale Hook. f., soaking for 8-14h, performing distillation extraction for 10-14h until the volume of volatile oil is not increased any more, standing still, and removing supernatant. The invention further provides application of the Rhododendron nivale Hook. f. volatile oil in preparation of a medicine for treating animal acariasis. The maximum yield of the Rhododendron nivale Hook. f. volatile oil is 2.45%; and 76 kinds of compounds are obtained by an improved GC-MS chromatographic method. The Rhododendron nivale Hook. f. volatile oil provided by the invention has a favorable therapeutic effect on animal acariasis, is of medicine concentration independence, and can be used for treating animal acariasis.
How Supplied: Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray (NDC 0378-3458-23) is supplied as an amber glass bottle fitted with a metered-dose spray pump unit. The spray pump unit consists of a nasal spray pump with a white nasal adapter and clear plastic dust cap. Each bottle contains a net fill weight of 23 g and will deliver 120 metered sprays after priming [see Dosage and Administration (2.2)]. After priming [see Dosage and Administration (2.2)], each spray delivers a suspension volume of 0.137 mL as a fine mist, containing 137 mcg of azelastine hydrochloride and 50 mcg of fluticasone propionate (137 mcg/50 mcg). The correct amount of medication in each spray cannot be assured before the initial priming and after 120 sprays have been used, even though the bottle is not completely empty. The bottle should be discarded after 120 sprays have been used.

Azelastine hydrochloride and fluticasone propionate nasal spray should not be used after the expiration date “EXP” printed on the bottle label and carton.

Storage: Store upright with the dust cap in place at controlled room temperature 20°C to 25°C (68°F to 77°F). [See USP Controlled Temperature] Protect from light. Do not store in the freezer or refrigerator.
Dermatomyositis (DM) is one of the major subtypes of idiopathic inflammatory myopathy. Prednisone is the initial treatment of choice in most patients with DM. However, because of the high rate of patients with disabling weakness despite treatment with prednisone, the long-term side effects of prednisone, and the many side effects associated with other second-line immunosuppressive agents (e.g., methotrexate, azathioprine), better treatment options are needed. There is evidence that tumor necrosis factor-a (TNF-a) plays a role in the pathogenesis of DM. Thus, etanercept, which blocks TNF-a, is a logical drug to assess in DM. Etanercept has been associated with a number of side effects including an increased risk of infection, inducing other autoimmune diseases, and perhaps cancer. These risks may be further enhanced in DM in which the frequency of other autoimmune disorders (e.g., connective tissue disease) and malignancy are already increased.

The goal of this pilot study will be to assess the safety and tolerability of etanercept in DM.We will perform a double-blind, placebo-controlled pilot study of etanercept in 40 patients with DM randomized in a 3:1 ratio to receive etanercept or placebo. All newly diagnosed and untreated patients will be started on a standard dose of prednisone and tapering schedule. Refractory patients who have been or are currently being treated with prednisone, IVIG, or methotrexate can also participate. Subjects will be followed for 1 year and we will assess various outcome variables recommended by the The International Myositis Assessment Clinical Study Group (IMACS). The primary aim of the study is to preliminarily assess the safety and tolerability of etanercept in patients with DM. We hypothesize that etanercept will be safe and well tolerated in this population. The second aim is to assess the safety and tolerability of prednisone in the dosing schedule we propose to use. We hypothesize that most patients will be able to tolerate the reduction of the prednisone dosage but most will not be able to be completely weaned off the medication. We believe we will find a relationship between prednisone dosage and its related side effects. The third aim of the study is to assess the variability, reliability, and responsiveness of the outcome measures recommended by IMACS using this pilot study of etanercept as the vehicle. The information gained from this study is necessary in order to design larger therapeutic trials of etanercept and other drugs in dermatomyositis.
PURPOSE: A stimulant for improving cognitive function is provided to inject liquid stimulant into user's nose by spraying and easily stimulate. CONSTITUTION: A liquid stimulant(100) contains solute selected from choline or cholinesalicylate and polar solvent in which the solute is dissolved. The stimulant 0.005-0.015 weight% of menthol to remove specific fishy smell of the choline and provides freshness for user. The content of the solute is 4-6 weight%. The polar solvent is water, methanol, or ethanol. The spray comprises the stimulant and spray container(200). The spray container has a nozzle(210) which enables spraying inside the nose.
In this study healthy people or those with knee arthritis so severe that they may need joint replacement are recruited for a one day study. Study participants will come to the Clinical Research Unit (CRU) and one intravenous (IV) catheter will be inserted in the forearm for oxytocin infusion. Participants in this study will receive oxytocin at a steady rate for 30 minutes. This information will be analyzed by another group at Stanford University in the Pharmacokinetic/Pharmacodynamic (PK/PD) Core part of this application. Mathematics will be utilized to calculate how quickly oxytocin moves from the blood to where it reduces pain.

Investigators will also do a pain test to determine how much oxytocin reduces pain. For this Investigators will place a probe on the skin and heat it to 113 - 117 degrees for 5 minutes. Study participants will score any pain they feel on a 0 to 10 scale, and most people find that pain rises during the 5 minutes, but remains mild, usually around only 1 or 2 on the 0 to 10 scale.
The invention provides a water-based nail polish. The water-based nail polish comprises an organic silicon modified water-based polyurethane dispersion, a water-based acrylic emulsion, a film-forming aid and water. The components of the water-based nail polish provided by the invention comprise an organic silicon modified water-based polyurethane dispersion, a water-based acrylic emulsion, a film-forming assistant and water. The organic silicon modified aqueous polyurethane dispersoid and the aqueous acrylic emulsion are used as film forming main bodies, so that the nail polish has good film forming property, and the cured nail film has higher strength. Particularly, the organosilicon modified aqueous polyurethane dispersion can obviously improve the whole strippable performance and the scratch resistance of the nail polish after film forming. Meanwhile, the film-forming assistant is added in a matching manner, so that the water-based nail polish disclosed by the invention has the characteristics of excellent moldability, capability of being stripped in a whole piece, matte and scratch resistance.
Despite the paucity of evidence on robotic ventral hernia repair (RVHR) in patients with obesity, the robotic platform is being used more frequently in hernia surgery. The impact of obesity on RVHR outcomes has not been thoroughly studied. Obesity is considered a major risk factor for the development of recurrent ventral hernias and postoperative complications; however, we hypothesize that patients undergoing robotic repairs will have similar complication profiles despite their body mass index (BMI). We performed a retrospective analysis of patients aged 18-90 years who underwent RVHR between 2013 and 2023 using data from the Abdominal Core Health Quality Collaborative registry. Preoperative, intraoperative, and postoperative characteristics were compared in non-obese and obese groups, determined using a univariate and logistic regression analysis to compare short-term outcomes. The registry identified 9742 patients; 3666 were non-obese; 6076 were classified as obese (BMI > 30 kg/m2). There was an increased odds of surgical site occurrence in patients with obesity, mostly seroma formation; however, obesity was not a significant factor for a complication requiring a procedural intervention after RVHR. In contrast, the hernia-specific quality-of-life scores significantly improved following surgery for all patients, with those with obesity having more substantial improvement from baseline. Obesity does increase the risk of certain complications following RVHR in a BMI-dependent fashion; however, the odds of requiring a procedural intervention are not significantly increased by BMI. Patients with obesity have a significant improvement in their quality of life, and RVHR should be carefully considered in this population.
A method for treating chronic wounds, where the wound is firstly washed with sterile saline. Then a piece of sterile nylon is prepared with mesh sizes which provide sufficient coverage of the wound, the mesh is placed over sterile gauze pad pre-moistened with saline. Saline, which contained larvae of green meat flies Lucilia Sericata, is poured on the mesh, and the number of larvae is 5-10 units per square centimeter of the affected area. The mesh is placed by larvae down and attached to hydrocolloid dressing or bandage with zinc paste. The central part of the bandage should not be blocked, the treatment of larvae is 24-72 hours depending on the condition of the wound. The course of treatment with larvae is ranged from 1 to 6 sessions, if necessary, it can be continued.
The intervention study information was delivered via print materials or access to a HD2 Web Site. Patients chose modality. In addition participants received two coaching calls from Health Coaches. ADDITIONAL NOTE: A sub-set of these participants was randomly selected to receive the Electronic Reminders through the intervention.
In the supraclavicular group, the ultrasound probe will be positioned in the supraclavicular fossa, pointing caudad and locating the subclavian artery. The first rib is identified deep to the artery, and the hyperechoic pleura will be identified by sliding lung sign. The brachial plexus is consistently found with a characteristic ''honeycomb'' appearance lateral and superficial to the subclavian artery and superior to the first rib. The needle will be introduced through the skin from lateral to medial, in-plane with the transducer, with constant visualization, and directed toward the deep border of the nerve group. Three separate injections will be made at various sites in the bundle, tending to start deep, in the ''corner pocket'' close to the artery, and moving more superficially. The local anesthetics will be Lidocaine 2% 10 ml + Levobupivacaine 0.5% 10 ml.
BACKGROUND: Gastrointestinal bleeding (GIB) results in frequent hospitalizations and impairs quality of life in durable left ventricular assist device (LVAD) recipients. Anticipation of these events before implantation could have important implications for patient selection and management.
METHODS: The study population included all adult HeartMate 3 (HM3) primary LVAD recipients enrolled in the STS Intermacs registry from January 2017 to December 2020. Using multivariable modeling methodologies, we investigated the relationships between preimplantation characteristics and postimplant bleeding, bleeding and death, and additional bleeding episodes on subsequent bleeding episodes and created a risk score to predict the likelihood of post-LVAD GIB based solely on preimplantation factors.
RESULTS: Of 6,425 patients who received an HM3 LVAD, 1,010 (15.7%) patients experienced GIB. Thirteen preimplantation factors were independent predictors of post-LVAD GIB. A risk score was created from these factors and calculated for each patient. By 3 years postimplant, GIB occurred in 11%, 26%, and 43% of low-, medium- and high-risk patients, respectively. Experiencing 1 post-LVAD GIB event was associated with an increased risk for further GIB events, with 33.9% of patients experiencing at least 1 recurrence. While post-LVAD GIB was associated with mortality, there was no relationship between number of GIB events and death.
CONCLUSIONS: The Michigan Bleeding Risk Model is a simple tool, which facilitates the prediction of post-LVAD GIB in HM3 recipients using 13 preimplant variables. The implementation of this tool may help in the risk stratification process and may have therapeutic and clinical implications in HM3 LVAD recipients.